An integrated strategy for Life Sciences in Europe

On Thursday, 4 June, AmCham EU’s Healthcare Committee hosted an online debate on its report 'Life Sciences in Europe – An integrated strategy for healthcare innovation (2019-2024)'. The panellists discussed the importance of building the resistance of health systems in Europe following the COVID-19 outbreak. A video recording of the event is available here

 

The event was opened by Susan Danger, CEO, AmCham EU. She spoke about the importance of the life sciences sector and its role in Europe’s economic recovery.

News
8 Jun 2020
Healthcare
An integrated strategy for Life Sciences in Europe

On Thursday, 4 June, AmCham EU’s Healthcare Committee hosted an online debate on its report 'Life Sciences in Europe – An integrated strategy for healthcare innovation (2019-2024)'. The panellists discussed the importance of building the resistance of health systems in Europe following the COVID-19 outbreak. A video recording of the event is available here

 

The event was opened by Susan Danger, CEO, AmCham EU. She spoke about the importance of the life sciences sector and its role in Europe’s economic recovery.

Before launching the panel into a discussion, the moderator, Philip Schwab (Abbvie), Issue lead on the life sciences for Europe report, AmCham EU asked the author of the report, Anthony Barron, Principal in the Life Sciences Practice, Charles River Associates to present his findings, taking into account the new challenges posed by the COVID-19 pandemic.

 

The panellists, Andrzej Rys, Director responsible for Health systems, medical products and innovation, DG SANTE, European Commission and Susana Solis Peres, MEP (Renew Europe, ES), European Parliament talked about the importance of reliable supply chains in Europe, investment in innovation and the digitalisation of healthcare.  

 

The speakers agreed that Europe cannot repeat the mistakes made during the previous economic crisis and that the well-being of citizens should remain at the centre of all policy making. The horizontal and integrated approach to life sciences technologies championed by the report was recognised as needed in Europe’s effort to sustainably improve its healthcare systems.

Related items

News
27 Oct 2025

Advancing EU health policy through competitiveness and innovation

On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda. 

Healthcare
Read more
Read more about Advancing EU health policy through competitiveness and innovation
News
9 Oct 2025

Advancing European healthcare in Strasbourg

From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation. 

Healthcare
Read more
Read more about Advancing European healthcare in Strasbourg
How the Critical Medicines Act will strengthen Europe’s life sciences sector
News
4 May 2025

How the Critical Medicines Act will strengthen Europe’s life sciences sector

On Wednesday, 30 April, Thibaut L'Ortye, Senior Director of Public Affairs, AmCham EU, joined a panel discussion on the Critical Medicines Act (CMA). Hosted by the European Policy Centre, Mr L'Ortye underlined the need for open and resilient supply chains to ensure continued access to medicines. He also highlighted the CMA’s potential to strengthen Europe's competitiveness and improve patient access. Avoiding protectionist measures and aligning the CMA with the EU’s wider simplification efforts is essential to attract investment into the Single Market. The discussion highlighted the importance of public-private collaboration to build a more competitive life sciences sector in the EU. 

Healthcare
Read more
Read more about How the Critical Medicines Act will strengthen Europe’s life sciences sector